Overview
- 77 inspections across 73 sites are on record.
- 109 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-03-26.
At a glance
Inspections
77
Sites
73
Observations
109
Career since
May 2015
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| ProtaGene GmbH | 26 Mar 2026 | Human Drugs | |
| Merck Serono SA | 25 Nov 2025 | Human Drugs | |
| Emergent BioSolutions Canada Inc. | 27 Aug 2025 | Human Drugs | On file |
| Aurolife Pharma LLC | 10 Apr 2025 | Human Drugs | On file |
| Ionetix Corporation | 6 Feb 2025 | Human Drugs | On file |
Sites inspected
ProtaGene GmbHDortmund, Germany1 insp.
Merck Serono SAAubonne, Switzerland1 insp.
Emergent BioSolutions Canada Inc.Winnipeg, Canada1 insp.
Aurolife Pharma LLCDurham, United States1 insp.
Ionetix CorporationKnoxville, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Vilmary Negron Rodriguez5 shared
Roger F Zabinski3 shared
Yiwei Li2 shared
Lane V Christensen2 shared
Esther C Broner2 shared
Thuy T Nguyen2 shared
Dennis Cantellops Paite2 shared
Ariel Cruz Figueroa2 shared
Binh T Nguyen2 shared
Djamila Harouaka2 shared
Full investigator report
Get the verbatim findings behind Laurimer Kuilan-Torres' 109 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site